Sen et al. [10] performed a post hoc analysis on the data of the CANVAS trial, consisting of a large and broad population of patients with T2DM and established cardiovascular disease, to examine the effect of the SGLT2 inhibitor canagliflozin on (amongst others) plasma KIM-1 and assessed whether early changes in the biomarker could predict cardiovascular, kidney, and heart failure outcomes. The gene discussed is SLC5A2; the disease is heart failure.